RxDoctor Payments Data

Mitchell Weinstein, MD

Infectious Disease · Chicago, ILNPI 1447270475

Payments from drug & device makers

$11,067in general payments, 2019–2025

Across 504 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$2K
  • Johnson & Johnson$1K
  • Merck$941
  • Melinta Therapeutics, LLC$723
  • AbbVie$515
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$4274%
  • Speaking & faculty fees$1031%
  • Food & beverage$10,37894%
  • Education$1591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,067 in reported general payments places this provider in the 80th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$113,180
Medicare patients
130
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala81$359,394
GenvoyaElviteg/Cob/Emtri/Tenof Alafen41$188,249
DovatoDolutegravir Sodium/Lamivudine43$135,137
PrezcobixDarunavir/Cobicistat46$129,524
JulucaDolutegravir/Rilpivirine25$122,164
TivicayDolutegravir Sodium38$106,798
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$64,007
TriumeqAbacavir/Dolutegravir/Lamivudi12$52,149
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df13$1,279
Methenamine Hippurate16$863
Atorvastatin Calcium35$427
Amlodipine Besylate19$138
Lisinopril11$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$3,378$547,643122 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Triumeq$2,331$416,248118 claims
Johnson & JohnsonPrezcobix$1,040$129,52446 claims
Janssen Products, LPSymtuza$60$64,00714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 368 infectious disease providers in Illinois.

Other infectious disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →